Inovio Pharmaceuticals, Inc.
INO
$2.65
$0.093.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.85% | 22.78% | 20.62% | 31.41% | 27.78% |
| Total Depreciation and Amortization | 8.25% | 0.09% | -10.66% | -45.92% | -44.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -111.88% | -112.46% | -84.51% | -82.12% | -0.44% |
| Change in Net Operating Assets | 3.47% | 47.67% | 74.02% | -184.90% | 65.00% |
| Cash from Operations | 15.63% | 12.25% | 16.31% | 17.66% | 34.97% |
| Capital Expenditure | 81.49% | -760.00% | -52.04% | -0.39% | 14.82% |
| Sale of Property, Plant, and Equipment | -60.01% | -60.01% | -99.05% | -97.56% | -97.56% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.03% | -48.01% | 28.29% | -22.55% | -57.74% |
| Cash from Investing | -22.70% | -48.45% | 19.13% | -26.39% | -59.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -40.36% | 199.23% | 560.97% | 141.54% | 85.22% |
| Repurchase of Common Stock | 72.78% | -48.33% | 9.86% | 9.86% | 16.02% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -0.51% | -- | -- | -- | -- |
| Cash from Financing | 27.24% | 1,174.43% | 930.52% | 145.99% | 87.10% |
| Foreign Exchange rate Adjustments | -100.00% | -100.00% | 930.77% | 316.46% | 566.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 45.19% | 335.21% | 260.85% | 190.56% | -257.79% |